Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Colorectal Neoplasms

  Free Subscription

Articles published in Br J Cancer

Retrieve available abstracts of 131 articles:
HTML format

Single Articles

    July 2022
  1. CHAKROBORTY D, Goswami S, Fan H, Frankel WL, et al
    Neuropeptide Y, a paracrine factor secreted by cancer cells, is an independent regulator of angiogenesis in colon cancer.
    Br J Cancer. 2022 Jul 28. pii: 10.1038/s41416-022-01916.
    PubMed     Abstract available

  2. FOERSCH S, Lang-Schwarz C, Eckstein M, Geppert C, et al
    pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas-proposal for a new pT3a/pT3b subclassification.
    Br J Cancer. 2022 Jul 21. pii: 10.1038/s41416-022-01889.
    PubMed     Abstract available

  3. RAMSAY RG, Flood M
    New insights into the unique nature of colorectal cancer peritoneal metastases-rethinking HIPEC.
    Br J Cancer. 2022 Jul 13. pii: 10.1038/s41416-022-01905.
    PubMed     Abstract available

  4. PANG X, Xie P, Yu L, Chen H, et al
    A new magnetic resonance imaging tumour response grading scheme for locally advanced rectal cancer.
    Br J Cancer. 2022;127:268-277.
    PubMed     Abstract available

  5. SONG M, Li S, Wang H, Hu K, et al
    MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer.
    Br J Cancer. 2022;127:249-257.
    PubMed     Abstract available

    June 2022
  6. ZAMAN FY, Orchard SG, Haydon A, Zalcberg JR, et al
    Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies.
    Br J Cancer. 2022 Jun 28. pii: 10.1038/s41416-022-01882.
    PubMed     Abstract available

  7. ARORA SP, Tenner L, Sarantopoulos J, Morris J, et al
    Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC).
    Br J Cancer. 2022 Jun 23. pii: 10.1038/s41416-022-01892.
    PubMed     Abstract available

  8. HASHIMOTO T, Takayanagi D, Yonemaru J, Naka T, et al
    Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01880.
    PubMed     Abstract available

  9. MORETTO R, Elliott A, Rossini D, Intini R, et al
    Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
    Br J Cancer. 2022 Jun 3. pii: 10.1038/s41416-022-01852.
    PubMed     Abstract available

  10. DI MARTINO E, Smith L, Bradley SH, Hemphill S, et al
    Incidence trends for twelve cancers in younger adults-a rapid review.
    Br J Cancer. 2022;126:1374-1386.
    PubMed     Abstract available

  11. KLEIF J, Jorgensen LN, Hendel JW, Madsen MR, et al
    Early detection of colorectal neoplasia: application of a blood-based serological protein test on subjects undergoing population-based screening.
    Br J Cancer. 2022;126:1387-1393.
    PubMed     Abstract available

  12. GINER-CALABUIG M, De Leon S, Wang J, Fehlmann TD, et al
    Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential.
    Br J Cancer. 2022;126:1595-1603.
    PubMed     Abstract available

  13. LI H, van der Merwe PA, Sivakumar S
    Biomarkers of response to PD-1 pathway blockade.
    Br J Cancer. 2022;126:1663-1675.
    PubMed     Abstract available

  14. LI Z, Wang K, Shivappa N, Hebert JR, et al
    Inflammatory potential of diet and colorectal carcinogenesis: a prospective longitudinal cohort.
    Br J Cancer. 2022;126:1735-1743.
    PubMed     Abstract available

    May 2022
  15. JUNG SH, Kim D, Park JW
    Reply to comment(s) on "Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index".
    Br J Cancer. 2022 May 31. pii: 10.1038/s41416-022-01862.

  16. XIE H, Ge Y, Shi H
    Comment on "Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index".
    Br J Cancer. 2022 May 31. pii: 10.1038/s41416-022-01861.

  17. FISCHER LE, Stintzing S, von Weikersthal LF, Modest DP, et al
    Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
    Br J Cancer. 2022 May 30. pii: 10.1038/s41416-022-01854.
    PubMed     Abstract available

  18. KIM S, Lim Y, Kang JK, Kim HP, et al
    Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment.
    Br J Cancer. 2022 May 28. pii: 10.1038/s41416-022-01837.
    PubMed     Abstract available

  19. UUTELA A, Osterlund E, Halonen P, Kallio R, et al
    Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study.
    Br J Cancer. 2022 May 24. pii: 10.1038/s41416-022-01858.
    PubMed     Abstract available

  20. YU L, Guo Q, Luo Z, Wang Y, et al
    TXN inhibitor impedes radioresistance of colorectal cancer cells with decreased ALDH1L2 expression via TXN/NF-kappaB signaling pathway.
    Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01835.
    PubMed     Abstract available

  21. SCHMID F, Dahlmann M, Rohrich H, Kobelt D, et al
    Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker.
    Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01833.
    PubMed     Abstract available

  22. GREENE G, Griffiths R, Han J, Akbari A, et al
    Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system.
    Br J Cancer. 2022 May 2. pii: 10.1038/s41416-022-01830.
    PubMed     Abstract available

    Editorial on "A systematic review of microbial markers for risk prediction of colorectal neoplasia" by Yu and coauthors.
    Br J Cancer. 2022;126:1239-1240.
    PubMed     Abstract available

  24. YU L, Zhao G, Wang L, Zhou X, et al
    A systematic review of microbial markers for risk prediction of colorectal neoplasia.
    Br J Cancer. 2022;126:1318-1328.
    PubMed     Abstract available

  25. MESSAOUDI N, Henault D, Stephen D, Cousineau I, et al
    Prognostic implications of adaptive immune features in MMR-proficient colorectal liver metastases classified by histopathological growth patterns.
    Br J Cancer. 2022;126:1329-1338.
    PubMed     Abstract available

    April 2022
  26. ELOMAA H, Ahtiainen M, Vayrynen SA, Ogino S, et al
    Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer.
    Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01822.
    PubMed     Abstract available

  27. BUCCHI L, Mancini S, Baldacchini F, Ravaioli A, et al
    How a faecal immunochemical test screening programme changes annual colorectal cancer incidence rates: an Italian intention-to-screen study.
    Br J Cancer. 2022 Apr 20. pii: 10.1038/s41416-022-01813.
    PubMed     Abstract available

  28. VAN CUTSEM E, Danielewicz I, Saunders MP, Pfeiffer P, et al
    First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.
    Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01737.
    PubMed     Abstract available

  29. CALLESEN LB, Hamfjord J, Boysen AK, Pallisgaard N, et al
    Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
    Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01816.
    PubMed     Abstract available

  30. BOGIE RMM, le Clercq CMC, Voorham QJM, Cordes M, et al
    Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case-control study.
    Br J Cancer. 2022;126:865-873.
    PubMed     Abstract available

    March 2022
  31. SOLIS-FERNANDEZ G, Montero-Calle A, Sanchez-Martinez M, Pelaez-Garcia A, et al
    Aryl-hydrocarbon receptor-interacting protein regulates tumorigenic and metastatic properties of colorectal cancer cells driving liver metastasis.
    Br J Cancer. 2022 Mar 28. pii: 10.1038/s41416-022-01762.
    PubMed     Abstract available

  32. STRATING E, Wassenaar E, Verhagen M, Rauwerdink P, et al
    Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by (68)Ga-FAPI-PET imaging.
    Br J Cancer. 2022 Mar 16. pii: 10.1038/s41416-022-01748.
    PubMed     Abstract available

  33. MAURI G, Vitiello PP, Sogari A, Crisafulli G, et al
    Liquid biopsies to monitor and direct cancer treatment in colorectal cancer.
    Br J Cancer. 2022 Mar 9. pii: 10.1038/s41416-022-01769.
    PubMed     Abstract available

  34. JUNG SH, Hao J, Shivakumar M, Nam Y, et al
    Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index.
    Br J Cancer. 2022 Mar 5. pii: 10.1038/s41416-022-01767.
    PubMed     Abstract available

  35. LASZLO HE, Seward E, Ayling RM, Lake J, et al
    Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review.
    Br J Cancer. 2022;126:736-743.
    PubMed     Abstract available

  36. LARSEN SG, Goscinski MA, Dueland S, Steigen SE, et al
    Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients.
    Br J Cancer. 2022;126:726-735.
    PubMed     Abstract available

    February 2022
  37. LAOUKILI J, Constantinides A, Wassenaar ECE, Elias SG, et al
    Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity.
    Br J Cancer. 2022 Feb 22. pii: 10.1038/s41416-022-01742.
    PubMed     Abstract available

  38. PATEL M, Pennel KAF, Quinn JA, Hood H, et al
    Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer.
    Br J Cancer. 2022 Feb 16. pii: 10.1038/s41416-022-01729.
    PubMed     Abstract available

  39. HAREWOOD R, Wooldrage K, Robbins EC, Kinross J, et al
    Adenoma characteristics associated with post-polypectomy proximal colon cancer incidence: a retrospective cohort study.
    Br J Cancer. 2022 Feb 11. pii: 10.1038/s41416-022-01719.
    PubMed     Abstract available

    January 2022
  40. THOMSEN MK, Pedersen L, Erichsen R, Lash TL, et al
    Risk-stratified selection to colonoscopy in FIT colorectal cancer screening: development and temporal validation of a prediction model.
    Br J Cancer. 2022 Jan 20. pii: 10.1038/s41416-022-01709.
    PubMed     Abstract available

  41. LAL N, Chan DKH, Ng ME, Vermeulen L, et al
    Primary tumour immune response and lymph node yields in colon cancer.
    Br J Cancer. 2022 Jan 18. pii: 10.1038/s41416-022-01700.
    PubMed     Abstract available

  42. TRAN TN, Peeters M, Hoeck S, Van Hal G, et al
    Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the "interval cancer" perspective.
    Br J Cancer. 2022 Jan 12. pii: 10.1038/s41416-021-01694.
    PubMed     Abstract available

  43. YCHOU M, Rivoire M, Thezenas S, Guimbaud R, et al
    Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
    Br J Cancer. 2022 Jan 6. pii: 10.1038/s41416-021-01644.
    PubMed     Abstract available

    December 2021
  44. GUO S, Li J, Huang Z, Yue T, et al
    The CBS-H2S axis promotes liver metastasis of colon cancer by upregulating VEGF through AP-1 activation.
    Br J Cancer. 2021 Dec 24. pii: 10.1038/s41416-021-01681.
    PubMed     Abstract available

  45. ADIB E, El Zarif T, Nassar AH, Akl EW, et al
    CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.
    Br J Cancer. 2021 Dec 23. pii: 10.1038/s41416-021-01673.
    PubMed     Abstract available

  46. ELEZ E, Gomez-Espana MA, Gravalos C, Garcia-Alfonso P, et al
    Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
    Br J Cancer. 2021 Dec 22. pii: 10.1038/s41416-021-01638.
    PubMed     Abstract available

  47. MCDOWELL R, Perrott S, Murchie P, Cardwell C, et al
    Oral antibiotic use and early-onset colorectal cancer: findings from a case-control study using a national clinical database.
    Br J Cancer. 2021 Dec 17. pii: 10.1038/s41416-021-01665.
    PubMed     Abstract available

  48. ZHANG X, Li X, He Y, Law PJ, et al
    Phenome-wide association study (PheWAS) of colorectal cancer risk SNP effects on health outcomes in UK Biobank.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01655.
    PubMed     Abstract available

  49. MATSUMOTO T, Okayama H, Nakajima S, Saito K, et al
    SH2D4A downregulation due to loss of chromosome 8p is associated with poor prognosis and low T cell infiltration in colorectal cancer.
    Br J Cancer. 2021 Dec 10. pii: 10.1038/s41416-021-01660.
    PubMed     Abstract available

    November 2021
  50. MANCA P, Corallo S, Lonardi S, Fuca G, et al
    Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01591.
    PubMed     Abstract available

  51. DASH P, Ghatak S, Topi G, Satapathy SR, et al
    High PGD2 receptor 2 levels are associated with poor prognosis in colorectal cancer patients and induce VEGF expression in colon cancer cells and migration in a zebrafish xenograft model.
    Br J Cancer. 2021 Nov 8. pii: 10.1038/s41416-021-01595.
    PubMed     Abstract available

  52. MAJANO SB, Lyratzopoulos G, Rachet B, de Wit NJ, et al
    Do presenting symptoms, use of pre-diagnostic endoscopy and risk of emergency cancer diagnosis vary by comorbidity burden and type in patients with colorectal cancer?
    Br J Cancer. 2021 Nov 5. pii: 10.1038/s41416-021-01603.
    PubMed     Abstract available

    October 2021
  53. TAKEDA T, Yokoyama Y, Takahashi H, Okuzaki D, et al
    A stem cell marker KLF5 regulates CCAT1 via three-dimensional genome structure in colorectal cancer cells.
    Br J Cancer. 2021 Oct 27. pii: 10.1038/s41416-021-01579.
    PubMed     Abstract available

  54. OUAHOUD S, Jacobs RJ, Kodach LL, Voorneveld PW, et al
    Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01604.
    PubMed     Abstract available

  55. OHSHIMA K, Oi R, Okuzaki D, Motooka D, et al
    Mitochondrial matrix protein C14orf159 attenuates colorectal cancer metastasis by suppressing Wnt/beta-catenin signalling.
    Br J Cancer. 2021 Oct 23. pii: 10.1038/s41416-021-01582.
    PubMed     Abstract available

  56. ARAI H, Xiao Y, Millstein J, Wang J, et al
    Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Br J Cancer. 2021 Oct 23. pii: 10.1038/s41416-021-01592.
    PubMed     Abstract available

  57. AASEBO K, Bruun J, Bergsland CH, Nunes L, et al
    Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01586.
    PubMed     Abstract available

  58. KONUKIEWITZ B, Schmitt M, Silva M, Pohl J, et al
    Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin-eosin-based morphologic parameters from the WHO classification.
    Br J Cancer. 2021 Oct 6. pii: 10.1038/s41416-021-01553.
    PubMed     Abstract available

    September 2021
  59. ZHANG J, Nyvang D, Ibsen DB, Olsen A, et al
    Adherence to the Danish food-based dietary guidelines and risk of colorectal cancer: a cohort study.
    Br J Cancer. 2021 Sep 30. pii: 10.1038/s41416-021-01556.
    PubMed     Abstract available

  60. BRETAGNE JF, Carlo A, Piette C, Rousseau C, et al
    Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme.
    Br J Cancer. 2021 Sep 12. pii: 10.1038/s41416-021-01546.
    PubMed     Abstract available

  61. CHEN D, Bao X, Zhang R, Ding Y, et al
    Depiction of the genomic and genetic landscape identifies CCL5 as a protective factor in colorectal neuroendocrine carcinoma.
    Br J Cancer. 2021;125:994-1002.
    PubMed     Abstract available

  62. LIU Z, Thong MSY, Doege D, Koch-Gallenkamp L, et al
    Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
    Br J Cancer. 2021;125:877-883.
    PubMed     Abstract available

    July 2021
  63. ZABOROWSKI AM, Winter DC, Lynch L
    The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review.
    Br J Cancer. 2021 Jul 23. pii: 10.1038/s41416-021-01475.
    PubMed     Abstract available

  64. FURTADO FS, Suarez-Weiss KE, Vangel M, Clark JW, et al
    Clinical impact of PET/MRI in oligometastatic colorectal cancer.
    Br J Cancer. 2021 Jul 19. pii: 10.1038/s41416-021-01494.
    PubMed     Abstract available

  65. ZOLTICK ES, Smith-Warner SA, Yuan C, Wang M, et al
    Sugar-sweetened beverage, artificially sweetened beverage and sugar intake and colorectal cancer survival.
    Br J Cancer. 2021 Jul 15. pii: 10.1038/s41416-021-01487.
    PubMed     Abstract available

  66. TEN HOORN S, Sommeijer DW, Elliott F, Fisher D, et al
    Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.
    Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01477.
    PubMed     Abstract available

  67. WANG X, Liu Q, Halfdanarson OO, Zoega H, et al
    Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study.
    Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01480.
    PubMed     Abstract available

  68. MORETTO R, Rossini D, Conca V, Lonardi S, et al
    CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
    Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01483.
    PubMed     Abstract available

  69. HUA X, Kratz M, Malen RC, Dai JY, et al
    Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients.
    Br J Cancer. 2021 Jul 6. pii: 10.1038/s41416-021-01458.
    PubMed     Abstract available

  70. MELTZER S, Torgunrud A, Abrahamsson H, Solbakken AM, et al
    The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer.
    Br J Cancer. 2021;125:240-246.
    PubMed     Abstract available

    June 2021
  71. LEE KH, Chen WS, Jiang JK, Yang SH, et al
    The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon.
    Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01470.
    PubMed     Abstract available

  72. LIN M, Fang Y, Li Z, Li Y, et al
    S100P contributes to promoter demethylation and transcriptional activation of SLC2A5 to promote metastasis in colorectal cancer.
    Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01306.
    PubMed     Abstract available

  73. GUO F, De Brabander I, Francart J, Candeur M, et al
    Correction: Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
    Br J Cancer. 2021 Jun 28. pii: 10.1038/s41416-021-01468.

  74. SEFRIOUI D, Beaussire L, Gillibert A, Blanchard F, et al
    CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
    Br J Cancer. 2021 Jun 10. pii: 10.1038/s41416-021-01431.
    PubMed     Abstract available

  75. DIXON SW, Collard TJ, Mortensson EMH, Legge DN, et al
    5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis.
    Br J Cancer. 2021;124:1959-1969.
    PubMed     Abstract available

    May 2021
  76. OUAHOUD S, Jacobs RJ, Peppelenbosch MP, Fuhler GM, et al
    Correction: Kinome-wide analysis of the effect of statins in colorectal cancer.
    Br J Cancer. 2021 May 10. pii: 10.1038/s41416-021-01426.

  77. SALVIANTI F, Gelmini S, Mancini I, Pazzagli M, et al
    Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
    Br J Cancer. 2021 May 5. pii: 10.1038/s41416-021-01399.
    PubMed     Abstract available

  78. FRIEND T, Stebbing J
    Profiling circulating tumour cells and cell free DNA together in metastatic colon cancer.
    Br J Cancer. 2021 May 5. pii: 10.1038/s41416-021-01397.
    PubMed     Abstract available

  79. KANE AM, Liu C, Fennell LJ, McKeone DM, et al
    Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia.
    Br J Cancer. 2021;124:1820-1827.
    PubMed     Abstract available

  80. AMADOU A, Freisling H, Jenab M, Tsilidis KK, et al
    Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
    Br J Cancer. 2021;124:1882-1890.
    PubMed     Abstract available

    April 2021
  81. CHEN KH, Lin LI, Yuan CT, Tseng LH, et al
    Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01300.
    PubMed     Abstract available

  82. LUND CM, Vistisen KK, Olsen AP, Bardal P, et al
    The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO).
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01367.
    PubMed     Abstract available

  83. KIM DW, Tan E, Zhou JM, Schell MJ, et al
    A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01368.
    PubMed     Abstract available

  84. BAXTER MA, Murphy J, Cameron D, Jordan J, et al
    The impact of COVID-19 on systemic anticancer treatment delivery in Scotland.
    Br J Cancer. 2021;124:1353-1356.
    PubMed     Abstract available

  85. KREGTING LM, Kaljouw S, de Jonge L, Jansen EEL, et al
    Effects of cancer screening restart strategies after COVID-19 disruption.
    Br J Cancer. 2021;124:1516-1523.
    PubMed     Abstract available

  86. THOMSON A, Bento DFC, Scurr MJ, Smart K, et al
    Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells.
    Br J Cancer. 2021;124:1552-1555.
    PubMed     Abstract available

    March 2021
  87. FEARON DT, Janowitz T
    AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
    Br J Cancer. 2021 Mar 26. pii: 10.1038/s41416-021-01315.
    PubMed     Abstract available

  88. GOLDER AM, McMillan DC, Park JH, Mansouri D, et al
    The prognostic value of combined measures of the systemic inflammatory response in patients with colon cancer: an analysis of 1700 patients.
    Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01308.
    PubMed     Abstract available

  89. OUAHOUD S, Jacobs RJ, Peppelenbosch MP, Fuhler GM, et al
    Kinome-wide analysis of the effect of statins in colorectal cancer.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01318.
    PubMed     Abstract available

  90. ROSENDAHL HUBER A, Pleguezuelos-Manzano C, Puschhof J
    A bacterial mutational footprint in colorectal cancer genomes.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01273.
    PubMed     Abstract available

  91. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
    The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
    PubMed     Abstract available

  92. YAEGASHI M, Iwaya T, Sasaki N, Fujita M, et al
    Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling.
    Br J Cancer. 2021 Mar 3. pii: 10.1038/s41416-021-01266.
    PubMed     Abstract available

  93. NIMPTSCH K, Lee DH, Zhang X, Song M, et al
    Dairy intake during adolescence and risk of colorectal adenoma later in life.
    Br J Cancer. 2021;124:1160-1168.
    PubMed     Abstract available

    February 2021
  94. SHANG Y, Zhang X, Lu L, Jiang K, et al
    Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01272.
    PubMed     Abstract available

  95. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available

  96. PINTO-FERNANDEZ A, Salio M, Partridge T, Chen J, et al
    Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity.
    Br J Cancer. 2021;124:817-830.
    PubMed     Abstract available

    January 2021
  97. ZHANG X, Theodoratou E, Li X, Farrington SM, et al
    Genetically predicted physical activity levels are associated with lower colorectal cancer risk: a Mendelian randomisation study.
    Br J Cancer. 2021 Jan 29. pii: 10.1038/s41416-020-01236.
    PubMed     Abstract available

  98. BAILEY SER, Abel GA, Atkins A, Byford R, et al
    Diagnostic performance of a faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: an evaluation in the South West of England.
    Br J Cancer. 2021 Jan 19. pii: 10.1038/s41416-020-01221.
    PubMed     Abstract available

  99. UENO H, Ishiguro M, Nakatani E, Ishikawa T, et al
    Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial).
    Br J Cancer. 2021 Jan 7. pii: 10.1038/s41416-020-01222.
    PubMed     Abstract available

  100. CULLIFORD R, Cornish AJ, Law PJ, Farrington SM, et al
    Lack of an association between gallstone disease and bilirubin levels with risk of colorectal cancer: a Mendelian randomisation analysis.
    Br J Cancer. 2021 Jan 7. pii: 10.1038/s41416-020-01211.
    PubMed     Abstract available

  101. BRAGAGNOLI AC, Araujo RLC, Ferraz MW, Dos Santos LV, et al
    Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01208.
    PubMed     Abstract available

    December 2020
  102. LOUGHREY MB, Fisher NC, McCooey AJ, Dunne PD, et al
    Comment on "Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes".
    Br J Cancer. 2020 Dec 14. pii: 10.1038/s41416-020-01213.

  103. YASUI K, Shida D, Nakamura Y, Ahiko Y, et al
    Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage III colorectal cancer patients.
    Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01189.
    PubMed     Abstract available

  104. ZELLWEGER M, Gonzalez M
    Comment on: the myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:1833-1834.

  105. MACBETH F, Fallowfield DL
    Reply to 'Comment on "The myth of pulmonary metastasectomy'".
    Br J Cancer. 2020;123:1835-1836.

    November 2020
  106. YU J, Li S, Xu Z, Guo J, et al
    CDX2 inhibits epithelial-mesenchymal transition in colorectal cancer by modulation of Snail expression and beta-catenin stabilisation via transactivation of PTEN expression.
    Br J Cancer. 2020 Nov 26. pii: 10.1038/s41416-020-01148.
    PubMed     Abstract available

  107. ALEXANDER PG, Roseweir AK, Pennel KAF, van Wyk HC, et al
    The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.
    Br J Cancer. 2020 Nov 23. pii: 10.1038/s41416-020-01168.
    PubMed     Abstract available

  108. JACOME AA, Vreeland TJ, Johnson B, Kawaguchi Y, et al
    The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.
    Br J Cancer. 2020 Nov 19. pii: 10.1038/s41416-020-01169.
    PubMed     Abstract available

  109. HUIJBERTS SCFA, Boelens MC, Bernards R, Opdam FL, et al
    Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.
    Br J Cancer. 2020 Nov 18. pii: 10.1038/s41416-020-01147.
    PubMed     Abstract available

  110. HEINEMANN V, von Weikersthal LF, Decker T, Kiani A, et al
    FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
    Br J Cancer. 2020 Nov 6. pii: 10.1038/s41416-020-01140.
    PubMed     Abstract available

  111. FANG Z, He M, Song M
    Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank.
    Br J Cancer. 2020 Nov 3. pii: 10.1038/s41416-020-01143.
    PubMed     Abstract available

  112. LI YY, Gao LJ, Zhang YX, Liu SJ, et al
    Bisphosphonates and risk of cancers: a systematic review and meta-analysis.
    Br J Cancer. 2020;123:1570-1581.
    PubMed     Abstract available

    October 2020
  113. CHA PH, Hwang JH, Kwak DK, Koh E, et al
    APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer.
    Br J Cancer. 2020 Oct 19. pii: 10.1038/s41416-020-01118.
    PubMed     Abstract available

  114. WENSINK GE, Elferink MAG, May AM, Mol L, et al
    Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
    Br J Cancer. 2020 Oct 13. pii: 10.1038/s41416-020-01076.
    PubMed     Abstract available

  115. ROSSINI D, Lonardi S, Antoniotti C, Santini D, et al
    Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01089.
    PubMed     Abstract available

  116. HE F, Ju HQ, Ding Y, Jiang Z, et al
    Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection.
    Br J Cancer. 2020;123:1244-1252.
    PubMed     Abstract available

    September 2020
  117. SIMIN J, Fornes R, Liu Q, Olsen RS, et al
    Antibiotic use and risk of colorectal cancer: a systematic review and dose-response meta-analysis.
    Br J Cancer. 2020 Sep 24. pii: 10.1038/s41416-020-01082.
    PubMed     Abstract available

  118. PAPE J, Magdeldin T, Stamati K, Nyga A, et al
    Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma.
    Br J Cancer. 2020;123:1178-1190.
    PubMed     Abstract available

  119. MURAHASHI S, Akiyoshi T, Sano T, Fukunaga Y, et al
    Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence.
    Br J Cancer. 2020;123:803-810.
    PubMed     Abstract available

    August 2020
  120. MACBETH F, Fallowfield L
    The myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:499-500.
    PubMed     Abstract available

    July 2020
  121. HOPPENER DJ, Nierop PMH, Hof J, Sideras K, et al
    Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis.
    Br J Cancer. 2020;123:196-206.
    PubMed     Abstract available

    June 2020
  122. ROOS VH, Kallenberg FGJ, van der Vlugt M, Bongers EJC, et al
    Addition of an online, validated family history questionnaire to the Dutch FIT-based screening programme did not improve its diagnostic yield.
    Br J Cancer. 2020;122:1865-1871.
    PubMed     Abstract available

    May 2020
  123. STREMITZER S, Vermeulen P, Graver S, Kockx M, et al
    Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases.
    Br J Cancer. 2020;122:1518-1524.
    PubMed     Abstract available

  124. QIN B, Zou S, Li K, Wang H, et al
    CSN6-TRIM21 axis instigates cancer stemness during tumorigenesis.
    Br J Cancer. 2020;122:1673-1685.
    PubMed     Abstract available

    April 2020
  125. DAI W, Wang G, Chwa J, Oh ME, et al
    Mitochondrial division inhibitor (mdivi-1) decreases oxidative metabolism in cancer.
    Br J Cancer. 2020;122:1288-1297.
    PubMed     Abstract available

  126. VAN GEEL RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, et al
    Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
    Br J Cancer. 2020;122:1166-1174.
    PubMed     Abstract available

    March 2020
  127. OTANDAULT A, Abraham JD, Al Amir Dache Z, Khalyfa A, et al
    Hypoxia differently modulates the release of mitochondrial and nuclear DNA.
    Br J Cancer. 2020;122:715-725.
    PubMed     Abstract available

  128. HERIOT AG
    Whither Anal Cancer?
    Br J Cancer. 2020;122:733-734.
    PubMed     Abstract available

  129. SEKHAR H, Malcomson L, Kochhar R, Sperrin M, et al
    Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014).
    Br J Cancer. 2020;122:749-758.
    PubMed     Abstract available

  130. APARICIO T, Bennouna J, Le Malicot K, Boige V, et al
    Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
    Br J Cancer. 2020;122:957-962.
    PubMed     Abstract available

    February 2020
  131. VAN DE BEEK I, Glykofridis IE, Wolthuis RMF, Gille HJJP, et al
    No evidence for increased prevalence of colorectal carcinoma in 399 Dutch patients with Birt-Hogg-Dube syndrome.
    Br J Cancer. 2020;122:590-594.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.